Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis

• Published in: BMC cancer 2012-01, Vol.12 (1), p.41-41, Article 41
• Main Authors: Yu, Ying-Hua, Wei, Wei, Liu, Jian-Lun
• Format: Article
• Language: English
• Subjects: Accuracy; Area Under Curve; Biopsy; Biopsy, Fine-Needle - methods; Biopsy, Fine-Needle - standards; Biopsy, Needle; Breast - pathology; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - surgery; Care and treatment; Chinese languages; Confidence intervals; Developing countries; Diagnosis; Female; Health aspects; Hospitals; Humans; Information management; LDCs; Medical diagnosis; Methods; Regression Analysis; Sensitivity and Specificity; Studies
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-12-41

Fine-needle aspiration biopsy (FNAB) of the breast is a minimally invasive yet maximally diagnostic method. However, the clinical use of FNAB has been questioned. The purpose of our study was to establish the overall value of FNAC in the diagnosis of breast lesions. After a review and quality assessment of 46 studies, sensitivity, specificity and other measures of accuracy of FNAB for evaluating breast lesions were pooled using random-effects models. Summary receiver operating characteristic curves were used to summarize overall accuracy. The sensitivity and specificity for the studies data (included unsatisfactory samples) and underestimation rate of unsatisfactory samples were also calculated. The summary estimates for FNAB in diagnosis of breast carcinoma were as follows (unsatisfactory samples was temporarily exluded): sensitivity, 0.927 (95% confidence interval [CI], 0.921 to 0.933); specificity, 0.948 (95% CI, 0.943 to 0.952); positive likelihood ratio, 25.72 (95% CI, 17.35 to 28.13); negative likelihood ratio, 0.08 (95% CI, 0.06 to 0.11); diagnostic odds ratio, 429.73 (95% CI, 241.75 to 763.87); The pooled sensitivity and specificity for 11 studies, which reported unsatisfactory samples (unsatisfactory samples was considered to be positive in this classification) were 0.920 (95% CI, 0.906 to 0.933) and 0.768 (95% CI, 0.751 to 0.784) respectively. The pooled proportion of unsatisfactory samples that were subsequently upgraded to various grade cancers was 27.5% (95% CI, 0.221 to 0.296). FNAB is an accurate biopsy for evaluating breast malignancy if rigorous criteria are used. With regard to unsatisfactory samples, futher invasive procedures are required in order to minimize the chance of a missed diagnosis of breast cancer.